The role of the genetically polymorphic CYP3A5 in the metabolism of CYP3A substrates is unclear. We investigated the contributions of the CYP3A4 and CYP3A5 isoforms to the metabolism of the phosphodiesterase type 5 inhibitors (PDE5Is) sildenafil, udenafil, and vardenafil. In vitro incubation studies of sildenafil N-demethylation, udenafil N-dealkylation, and vardenafil N-deethylation were conducted using recombinant CYP3A enzymes and 15 human liver microsome (HLM) preparations with predetermined CYP3A5 genotypes. Recombinant CYP3A4 and CYP3A5 both produced N-desalkyl metabolites of sildenafil, udenafil, and vardenafil. The catalytic efficiency (Cl(int) = V(max)/apparent K(m)) of the rCYP3A5 isoform for vardenafil N-deethylation was about 3.2-fold that of rCYP3A4, whereas the intrinsic clearance rates for N-dealkylation of both sildenafil and udenafil were similar between rCYP3A5 and rCYP3A4. The metabolite formation activity was higher in HLMs heterozygous for the CYP3A5*3 allele (n = 9) than in HLMs homozygous for CYP3A5*3 (n = 6). These findings suggest that CYP3A5 and CYP3A4 play a significant role in the metabolism of PDE5Is. The genetic polymorphism of CYP3A5 may contribute to interindividual variability in the disposition of PDE5Is, especially vardenafil. Further in vivo studies are needed to confirm the effects of CYP3A5 genotypes on the pharmacokinetics of PDE5Is.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1124/dmd.107.020099 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review.
Cureus
August 2024
Research, Ventolini's Lab, Texas Tech University Health Sciences Center, Odessa, USA.
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a severe lung disease marked by elevated pulmonary arterial pressure, causing symptoms that often lead to late diagnosis and a poor prognosis, with a median life expectancy of only three years.
- The condition involves a combination of factors leading to blockage and stiffening of blood vessels in the lungs, resulting in right heart strain and potential failure.
- A systematic review of recent studies evaluated various PAH treatments, highlighting that while many drugs show promise, most do not offer a cure and some, like imatinib, have undesirable side effects.
[Ultra-high performance liquid chromatography-orbitrap high-resolution mass spectrometry for rapid screening and identification of 32 illegally added drugs in slimming and anti-impotence health foods].
Se Pu
June 2022
Shanghai Institute of Quality Inspection and Technical Research, State Key Laboratory of Milk and Dairy Products Detection and Monitoring Technology for State Market Regulation, Shanghai 200233, China.
A novel method based on ultra-high performance liquid chromatography-orbitrap high-resolution mass spectrometry (UHPLC-Orbitrap HRMS) was developed for the rapid screening and confirmation of 32 illegally added drugs in slimming and anti-impotence health foods. In addition, the key points of the database establishment and application are summarized. This research focused on the derivatives of illegally added drugs.
View Article and Find Full Text PDFLodenafil.
Profiles Drug Subst Excip Relat Methodol
April 2022
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia; Department of Chemistry, Faculty of Science and Technology, Al-Neelain University, Khartoum, Sudan.
Article Synopsis
- Lodenafil is a PDE5 inhibitor used for erectile dysfunction, similar to medications like sildenafil and tadalafil.
- It is a prodrug that converts into two active lodenafil molecules in the body, offering better oral bioavailability than its parent compound.
- The article covers various aspects of lodenafil, including its composition, therapeutic uses, preparation methods, properties, and dosing guidelines.
A validated LC-MS/MS assay for the quantification of phosphodiesterase-5 inhibitors in human plasma.
J Chromatogr B Analyt Technol Biomed Life Sci
August 2021
Universidade Federal do Paraná, Department of Pharmacy, 632 Lothário Meissner Avenue, 80210-170 Curitiba, PR, Brazil. Electronic address:
Phosphodiesterase inhibitors (PDE5i) are considered the first line therapy for erectile dysfunction. All PDE5i available on the market are structurally related; their main differences relate to their pharmacokinetic parameters. For these treatments to be effective and safe, it is necessary that these drugs are in the appropriate doses and that they reach adequate concentrations in the plasma.
View Article and Find Full Text PDF[Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Urologiia
May 2021
Tashkent Medical Academy, Tashkent, Uzbekistan.
This article discusses the physiological mechanisms of erection and the pathophysiological basis of erectile dysfunction. Parameters characterizing the features of the pharmacokinetics and pharmacodynamics of drugs from the group of phosphodiesterase type 5 inhibitors (PDE-5i) are presented. The clinical efficacy and possible adverse effects of the most significant PDE-5i are considered.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!